Abstract
Sulindac is a long-acting nonsteroidal anti-inflammatory drug (NSAID) widely used for the management of osteoarthritis, rheumatoid arthritis, ankylosing sponydlitis, and acute gouty arthritis. Reports of sulindac toxicity in the literature are rare. We report the case of a 22-year old male with a history of bipolar disorder who was brought to the emergency department after ingesting approximately 15 g of sulindac in a suicide attempt. He was found to have acute kidney injury and hyperbilirubinemia. Despite aggressive fluid resuscitation, his renal function progressively worsened requiring the initiation of hemodialysis. Ten days following ingestion of sulindac, he began to develop ischemic skin changes with a gangrenous appearance in his hands and feet. He continued to receive supportive treatment, and his acute kidney injury, hyperbillirubinemia, and ischemic skin necrosis eventually resolved. Clinicians should be aware of this long-acting NSAID and its ability to cause prolonged multisystem organ dysfunction.
Keywords: Clinoril, hepatotoxicity, nephrotoxicity, NSAID, overdose, sulindac.
Current Drug Safety
Title:Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose
Volume: 10 Issue: 2
Author(s): John L. Vaughn, Kejal V. Shah, Maroun M. Ghossein, William L. Meyer and Robert B. Kirkpatrick
Affiliation:
Keywords: Clinoril, hepatotoxicity, nephrotoxicity, NSAID, overdose, sulindac.
Abstract: Sulindac is a long-acting nonsteroidal anti-inflammatory drug (NSAID) widely used for the management of osteoarthritis, rheumatoid arthritis, ankylosing sponydlitis, and acute gouty arthritis. Reports of sulindac toxicity in the literature are rare. We report the case of a 22-year old male with a history of bipolar disorder who was brought to the emergency department after ingesting approximately 15 g of sulindac in a suicide attempt. He was found to have acute kidney injury and hyperbilirubinemia. Despite aggressive fluid resuscitation, his renal function progressively worsened requiring the initiation of hemodialysis. Ten days following ingestion of sulindac, he began to develop ischemic skin changes with a gangrenous appearance in his hands and feet. He continued to receive supportive treatment, and his acute kidney injury, hyperbillirubinemia, and ischemic skin necrosis eventually resolved. Clinicians should be aware of this long-acting NSAID and its ability to cause prolonged multisystem organ dysfunction.
Export Options
About this article
Cite this article as:
Vaughn L. John, Shah V. Kejal, Ghossein M. Maroun, Meyer L. William and Kirkpatrick B. Robert, Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose, Current Drug Safety 2015; 10 (2) . https://dx.doi.org/10.2174/157488631002150515150729
DOI https://dx.doi.org/10.2174/157488631002150515150729 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple Roles for Chemokines in the Pathogenesis of SIV Infection
Current HIV Research Preface (Hot Topic: Regulatory Peptides Executive Editor: Dr. Nese Tuncel)
Current Pharmaceutical Design Pharmaceutical Approaches for Optimizing Oral Anti-Inflammatory Delivery Systems
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [ Hot Topic: Current Drug Targets in Degenerative Joint Disease (Guest Editors: T. Aigner and E. Bartnik) ]
Current Drug Targets Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents Impaired Expression and Function of Cancer-Related Enzymes by Anthocyans: An Update
Current Enzyme Inhibition New Potential Serum Biomarkers in Multiple Sclerosis Identified by Proteomic Strategies
Current Medicinal Chemistry The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets
Current Drug Targets Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews Stem Cells and Translational Medicine: From Research to Clinical Procedures
Current Tissue Engineering (Discontinued) Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Misfolded Proteins and Human Diseases
Protein & Peptide Letters Ankylosing Spondylitis, Late Osteoarthritis, Vascular Calcification, Chondrocalcinosis and Pseudo Gout: Toward a Possible Drug Therapy
Current Medicinal Chemistry Editorial [Hot topic: Utilization of Biology Therapy in Spondyloarthropathy (SpA) in Asia Countries (Guest Editor: Chung-Tei Chou)]
Current Rheumatology Reviews Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis
Current Pharmacogenomics and Personalized Medicine Preparation of 2-(4-{[4-(Quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl) Propionic Acid (VUFB 20615) and 2-Methyl-2-(4-{[4-(quinolin-2- ylmethoxy)Phenyl]sulfanyl}phenyl)Propionic Acid (VUFB 20623) as Potential Antileukotrienic Agents
Current Organic Chemistry Pharmacological and Biological Therapies for Metabolic Bone Disease in Critical Illness: An Integrative Physiology Approach
Current Drug Therapy Psychosomatic Features, Compliance and Complementary Therapies in Rheumatoid Arthritis
Current Rheumatology Reviews The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research